PD-L1 and TMB Testing of Patients with Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies
- MeSH Terms
Carcinoma, Large Cell (C04.557.470.200.260); Carcinoma, Non-Small-Cell Lung (C04.588.894.797.520.109.220.249); Adenocarcinoma of Lung (C04.557.470.200.025.022); B7-H1 Antigen (D12.776.465.625); Programmed Cell Death 1 Receptor (D12.776.465.844)
- Guideline Contact
- Christina Ventura ([email protected])
- Keywords
- Adenocarcinoma, Lung, NSCLC, Non-small-cell lung cancer, non-small-cell lung carcinoma, respiratory, pulmonary, neoplasm, tumor, tumour, cancer, carcinoma, squamous cell, large cell, adenosquamous, Sarcomatoid, B7 H1, B7H, B7-H1, PD L1, PD-L1, PDL-1, CD274, CD 274, Tmb, tumo?r mutation*load, tumo?r mutation* burden, programmed cell death 1, programmed cell death 1 receptor, CD279, CD 279
- Publication Date
- April 16, 2024
- Countries of Application
- United States
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- CAP (US)
- Publication Year
- 2024